Ototoxicity in children receiving cisplatin chemotherapy

Abstract

- The underlying diseases were osteosarcoma (15 cases), medulloblastoma (14 cases), germ cell tumors (7 cases), and hepa- toblastoma (1 case). The median individual dose was 100 mg/m 2 /cycle (56-200). The median cumulative dose was 480 mg/m 2 (200-1,490). Sixteen patients (43%) received cranial radiotherapy. Of the 37 patients, 17 developed hearing loss, leading to an overall incidence of 46%. Logistic regression showed that age at treatment (P=0.04) and cumulative dose of cisplatin (P =0.005) were the significant risk factors in predicting hearing loss in children treated with cisplatin. In all the patients who had hearing loss, there was neither improvement nor aggravation during the follow-up (3 68 months). - Conclusion : The cumulative dose of cisplatin (>500 mg/m 2 ) and younger age at treatment (<12 years) were 2 most important risk factors for ototoxicity in patients treated with cisplatin. Serial audiometric evaluations are needed in the patients with risk factors during and after cisplatin treatment. (Korean J Pediatr 2010;53:210-214)